STOCK TITAN

GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags

GRAIL (Nasdaq: GRAL) granted inducement equity awards under Nasdaq Listing Rule 5635(c)(4) to recent hires on Dec. 1, 2025. The company issued restricted stock units totaling 21,570 shares to 21 non-executive employees under its Inducement Equity Incentive Plan as an employment inducement.

The RSUs vest over an approximately four-year schedule, with 25% vesting on Nov. 30, 2026 and the remainder vesting on each one-year anniversary thereafter, subject to continued employment with GRAIL or its successor/subsidiary.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

News Market Reaction

-0.91%
34 alerts
-0.91% News Effect
-5.3% Trough in 6 hr 1 min
-$37M Valuation Impact
$4.03B Market Cap
1.0x Rel. Volume

On the day this news was published, GRAL declined 0.91%, reflecting a mild negative market reaction. Argus tracked a trough of -5.3% from its starting point during tracking. Our momentum scanner triggered 34 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $37M from the company's valuation, bringing the market cap to $4.03B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Inducement RSUs: 21,570 shares Employees granted: 21 employees Vesting period: 4 years +1 more
4 metrics
Inducement RSUs 21,570 shares RSUs granted to new non-executive employees
Employees granted 21 employees Recipients of inducement RSU awards
Vesting period 4 years RSUs vest over approximately four years
Initial vesting tranche 25% of award Vests on Nov. 30, 2026

Market Reality Check

Price: $106.31 Vol: Volume 638,858 vs 20-day ...
low vol
$106.31 Last Close
Volume Volume 638,858 vs 20-day average 1,209,973 (relative volume 0.53x). low
Technical Price $95.09 trades above 200-day MA $48.66 and 17.86% below 52-week high $115.76.

Peers on Argus

Peers showed mixed moves: NEOG +0.86%, OPK +0.72%, CDNA +3.5% versus TWST -1.23%...

Peers showed mixed moves: NEOG +0.86%, OPK +0.72%, CDNA +3.5% versus TWST -1.23% and NEO -2.32%, suggesting stock-specific factors for GRAL.

Historical Context

5 past events · Latest: Dec 01 (Neutral)
Pattern 5 events
Date Event Sentiment Move Catalyst
Dec 01 Inducement equity grants Neutral -0.9% RSU inducement awards to 21 new non-executive employees.
Nov 18 Conference presentation Neutral -4.1% Planned presentation at Piper Sandler healthcare conference.
Nov 12 Earnings results Positive +1.6% Q3 2025 revenue growth, narrowed net loss, strong cash position.
Nov 04 Conference presentation Neutral +4.9% Announcement of participation in Wolfe Research healthcare conference.
Oct 29 Earnings date notice Neutral -1.3% Notification of Q3 2025 earnings release and Analyst Day schedule.
Pattern Detected

Recent news has produced modest price reactions, with earnings showing positive alignment while conference and routine announcements sometimes see moves without clear fundamental drivers.

Recent Company History

Over the last few months, GRAIL reported Q3 2025 results on Nov 12 with revenue growth and narrowed losses, which coincided with a +1.65% move. Multiple conference and event announcements on Oct 29, Nov 4, and Nov 18 led to single‑digit moves in both directions. The current Dec 1 inducement RSU grants continue a pattern of routine corporate updates with relatively limited historical price impact.

Market Pulse Summary

This announcement details inducement equity awards of 21,570 RSU shares to 21 new non-executive empl...
Analysis

This announcement details inducement equity awards of 21,570 RSU shares to 21 new non-executive employees under a dedicated plan compliant with Nasdaq Listing Rule 5635(c)(4). The RSUs vest over about four years, with 25% vesting on Nov. 30, 2026. In the broader context, recent quarters featured revenue growth and capital-raising transactions, so investors may watch how ongoing hiring and equity incentives support execution of those strategic plans.

Key Terms

restricted stock units, rsus, nasdaq listing rule 5635(c)(4), inducement equity incentive plan, +1 more
5 terms
restricted stock units financial
"granted equity awards in the form of restricted stock units ("RSUs")"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
rsus financial
"in the form of restricted stock units ("RSUs") underlying an aggregate of 21,570"
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
nasdaq listing rule 5635(c)(4) regulatory
"agreement in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
inducement equity incentive plan financial
"awards were granted under GRAIL's Inducement Equity Incentive Plan and related"
An inducement equity incentive plan is a program that grants employees or executives company shares or stock options to motivate and reward their work, often as a way to attract new talent. It aligns their interests with the company's success, encouraging them to contribute to long-term growth. For investors, such plans can influence a company's stock performance and overall financial health by motivating key personnel.
vesting financial
"The RSUs vest over an approximately four year period, with 25% of the award vesting"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

AI-generated analysis. Not financial advice.

MENLO PARK, Calif., Dec. 1, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 21,570 shares of GRAIL's common stock to 21 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL. The employment inducement awards were granted under GRAIL's Inducement Equity Incentive Plan and related form of restricted stock award agreement in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement plan is used exclusively for the grant of equity awards to individuals who were not previously employees of GRAIL, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with GRAIL, pursuant to Nasdaq Listing Rule 5635(c)(4).

The RSUs vest over an approximately four year period, with 25% of the award vesting Nov. 30, 2026, and on each one year anniversary of those respective dates thereafter, subject to continued employment with GRAIL (or any successor to or subsidiary of the Company) through the vesting dates.

About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom.

For more information, visit grail.com.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302629435.html

SOURCE GRAIL, Inc.

FAQ

What did GRAIL (GRAL) announce on December 1, 2025 about equity awards?

GRAIL announced inducement restricted stock unit grants totaling 21,570 shares to 21 recently hired non-executive employees under Nasdaq Rule 5635(c)(4).

How do the GRAIL (GRAL) RSUs vest and when is the first vesting date?

The RSUs vest over an approximately four-year schedule, with 25% vesting on Nov. 30, 2026 and annual vesting on each one-year anniversary thereafter.

Under which plan were GRAIL (GRAL) inducement awards granted?

The awards were granted under GRAIL's Inducement Equity Incentive Plan and the company's restricted stock award agreement in accordance with Nasdaq Listing Rule 5635(c)(4).

Who were the recipients of the GRAIL (GRAL) inducement RSUs?

The RSUs were granted to 21 recently hired non-executive employees as an inducement material to their acceptance of employment.

Do GRAIL (GRAL) inducement RSUs require continued employment to vest?

Yes. Vesting is subject to continued employment with GRAIL (or any successor or subsidiary) through each vesting date.

Was the GRAIL (GRAL) grant made in compliance with Nasdaq rules?

Yes. The company stated the grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) for inducement awards.
Grail Inc

NASDAQ:GRAL

GRAL Rankings

GRAL Latest News

GRAL Latest SEC Filings

GRAL Stock Data

4.09B
35.08M
13.81%
73.53%
13.42%
Diagnostics & Research
Services-medical Laboratories
Link
United States
MENLO PARK